

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1548)**

## **INSIDE INFORMATION**

### **COMPLETION OF ACQUISITION OF SHARES BY A SUBSTANTIAL SHAREHOLDER FROM A CONTROLLING SHAREHOLDER**

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”) dated 13 December 2023 in relation to, among others, the acquisition of shares by a substantial shareholder from a controlling shareholder (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

This announcement is made by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

### **COMPLETION OF ACQUISITION OF SHARES BY A SUBSTANTIAL SHAREHOLDER FROM A CONTROLLING SHAREHOLDER**

The Company has been informed by GS Corp that it completed the sale of 8,578,000 Shares to the Purchaser on 19 December 2023 pursuant to the agreement relating to the Acquisition.

### **EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY**

The table below sets out a summary of the shareholding structure of the Company (i) before the completion of the Acquisition; and (ii) as at the date of this announcement and following the completion of the Acquisition:

	Before the Completion of the Acquisition		As at the date of this announcement and following the Completion of the Acquisition	
	Number of Shares held	%	Number of Shares held	%
Genscript Corporation <sup>(Note 1)</sup>	808,577,123	38.09	799,999,123	37.68
- GNS Holdings Limited <sup>(Note 2)</sup>	164,770,965	7.76	164,770,965	7.76
- GNS II Holdings Limited (the Purchaser) <sup>(Note 2)</sup>	-	-	8,578,000	0.40
Other shareholders of the Company	1,149,589,070	54.15	1,149,589,070	54.15
Total issued Shares	<u>2,122,937,158</u>	<u>100.00</u>	<u>2,122,937,158</u>	<u>100.00</u>

*Note:*

- Genscript Corporation is a company incorporated in the State of Delaware in the U.S. and owned as to approximately 5.12%, approximately 21.34%, approximately 4.60%, approximately 4.60%, approximately 4.60%, approximately 22.76%, approximately 0.25%, approximately 3.99%, approximately 3.72%, approximately 3.72%, approximately 2.45%, approximately 4.76%, approximately 3.77%, approximately 3.79%, approximately 8.42%, approximately 1.05% and approximately 1.07% by Zhang Fangliang, the Zhang Trust, the Zhang 2023 Trust, Jin Weihong, the Jin 2023 Trust, Wang Luquan, Wu Yongmei, the Wu 2017 Trust, the Wu 2020 Separate Trust A, the Wu 2020 Separate Trust L, the Wu 2021 Trust, the Wu 2022 Trust, the Wu 2023 Trust, Wang Ye, the Wang Trust, Mu Yingjun and Charity B, respectively.
- HIML is the sole investment manager of each of GNS Holdings Limited and the Purchaser.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 19 December 2023

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai*

*\* For identification purposes only*